Cor.At CardioEffect Screening
Cor.At® cardiomyocytes in combination with Roche's RTCA Cardio instrument provide a standardized, homogenous and reproducible cell system for the in vitro detection of a compound‘s potential to influence spontaneous beating, e.g. frequency and rhythmicity. Using our optimized protocol, Cor.At® cardiomyocytes are cultured in E-Plates Cardio 96, and treated with 5 concentrations of the test compounds. Results obtained in the study will indicate a potential effect on cardiac beating, e.g. changes of beating frequency, induction of arrhythmia, or beating arrest.
Cor.At® cardiomyocytes provide a physiologically relevant and predictive in vitro model for cardiac safety screening in early lead optimization. Results obtained in our electrophysiology services can therefore be compared directly with results obtained in our cellular toxicity services, e.g. the Cor.At® Tox Test. This improves the ability to determine potential cardiotoxic effects of compounds in early stages of drug development, providing better measures to move lead compounds towards pre-clinical and clinical development.
The Cor.At® CardioEffect Screening has been validated in house using 24 drugs with known cardiac safety profile. The assay correctly predicted 23 of the compounds (1 false negative due to species differences). Reference compounds are included on each assay plate to ensure reproducible results.




